HDAC9 and non-small cell lung carcinoma: A phase II study in NSCLC of carboplatin and paclitaxel with randomization to the HDAC inhibitor vorinostat demonstrated a superior response rate (34.0 vs. 12.5%, p = 0.02) in the vorinostat arm with a trend toward an improvement in survival (Ramalingam et al., 2010).